# Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

> **NCT03874273** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 25 (estimated)

## Conditions studied

- Inflammatory Myofibroblastic Tumor

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT03874273
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-01
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874273, "Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03874273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*